Company / R&D per Share
Enliven Therapeutics, Inc. R&D per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.72
FY2024
5-year range
$1.72 / $9.93
FY2020-FY2024
Trend
-5.5%
vs FY2023
Sector context
#114 of 208
Health Care
What the data says
At $1.72, Enliven Therapeutics, Inc.'s r&d per share ranks #114 of 208 in the Health Care sector. Declined from $9.93 to $1.72 over the past 2 years.
Based on SEC 10-K filings.
1.72 in FY2024 with a 5-year CAGR of -42.4%.
Declined from $9.93 to $1.72 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -1.1%
- 5-Year CAGR
- -42.4%
- 10-Year CAGR
- -
Sector benchmark
#114 of 208 in Health CareTop 55% of 208This company $1.72 Sector average $12.19
▼
-85.9% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 5.5% year-over-year.
- Ranks #114 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.72 | -5.5% |
| FY2023 | $1.82 | -81.7% |
| FY2022 | $9.93 | +459.5% |
| FY2021 | $1.77 | -23.1% |
| FY2020 | $2.31 | -91.5% |
| FY2019 | $27.06 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026